🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are escalating around the world, with data suggesting in excess of 82 million new cases each year. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the very limited available drugs at this time.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone marks a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Data and Global Access

According to data detailed in a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The trial enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to license and sell the drug in numerous regions with limited resources.

Doctors treating patients have shared optimism. The availability of a one-pill regimen of this kind is seen as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.